Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>,...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bc719c3f63ca4dcc8b8fbc8c3bbac62d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>, 25 <i>Ureaplasma urealyticum,</i> and 40 <i>Mycoplasma hominis</i>). All <i>Mycoplasma hominis</i> isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC<sub>50/90</sub> of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while <i>Ureaplasma</i> isolates had MICs of ≤2 mg/L after 24 h (MIC<sub>50/90</sub> of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two <i>U. urealyticum</i> isolates with additional A2058G mutations of 23S rRNA, and one <i>U. parvum</i> isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating <i>Ureaplasma</i> spp. and <i>Mycoplasma hominis</i> infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of <i>Mycoplasma</i> and <i>Ureaplasma</i> urogenital infections is warranted. |
|---|